Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights
The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line
Lohmann, V., Körner, F., Koch, J.-O., Herian, U., Theilmann, L., & Bartenschlager, R. (1999) · Science · doi:10.1126/science.285.5424.110 · Cited by 2,814
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Kräusslich, H.-G., Mizokami, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1268 · Cited by 2,754
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515
Complete Replication of Hepatitis C Virus in Cell Culture
Lindenbach, B. D., Evans, M. J., Syder, A. J., Wölk, B., Tellinghuisen, T. L., Liu, C. C., Maruyama, T., Hynes, R. O., Burton, D. R., McKeating, J. A., et al. (2005) · Science · doi:10.1126/science.1114016 · Cited by 2,238
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
Robust hepatitis C virus infection in vitro
Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D. R., Wieland, S. F., Uprichard, S. L., Wakita, T., & Chisari, F. V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503596102 · Cited by 1,709
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., Romero-Gomez, M., Zarski, J.-P., Agarwal, K., Buggisch, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402454 · Cited by 1,705
Panel, A. H. G. (2015) · Hepatology · doi:10.1002/hep.27950 · Cited by 1,382
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316366 · Cited by 1,307
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A. S., Hinestrosa, F., Thuluvath, P. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306218 · Cited by 1,190
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., Shiffman, M. L., Schiff, E., Ghalib, R., Ryan, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402355 · Cited by 1,130
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Feld, J. J., Jacobson, I. M., Hézode, C., Asselah, T., Ruane, P. J., Gruener, N., Abergel, A., Mangia, A., Lai, C.-L., Chan, H. L. Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512610 · Cited by 1,106
Self-citationSofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090
Self-citationTelaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Hézode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.-P., Bourlière, M., Gharakhanian, S., Bengtsson, L., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807650 · Cited by 1,025
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
Lamarre, D., Anderson, P. C., Bailey, M., Beaulieu, P., Bolger, G., Bonneau, P., Bös, M., Cameron, D. R., Cartier, M., Cordingley, M. G., et al. (2003) · Nature · doi:10.1038/nature02099 · Cited by 917
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Feld, J. J., Kowdley, K. V., Coakley, E., Sigal, S., Nelson, D. R., Crawford, D., Weiland, O., Aguilar, H., Xiong, J., Pilot-Matias, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315722 · Cited by 903
Self-citationABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Poordad, F., Hezode, C., Trinh, R., Kowdley, K. V., Zeuzem, S., Agarwal, K., Shiffman, M. L., Wedemeyer, H., Berg, T., Yoshida, E. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402869 · Cited by 874
Weber, P. C., Lesburg, C. A., Cable, M., Ferrari, E., Hong, Z., & Mannarino, A. F. (1999) · Nature Structural Biology · doi:10.1038/13305 · Cited by 856
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Foster, G. R., Afdhal, N., Roberts, S. K., Bräu, N., Gane, E. J., Pianko, S., Lawitz, E., Thompson, A., Shiffman, M. L., Cooper, C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512612 · Cited by 846
Lawitz, E., Sulkowski, M. S., Ghalib, R., Rodriguez-Torres, M., Younossi, Z. M., Corregidor, A., DeJesus, E., Pearlman, B., Rabinovitz, M., Gitlin, N., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61036-9 · Cited by 818
Charlton, M., Everson, G. T., Flamm, S. L., Kumar, P., Landis, C., Brown, R. S., Fried, M. W., Terrault, N. A., O'Leary, J. G., Vargas, H. E., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.010 · Cited by 802
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Zeuzem, S., Dusheiko, G. M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R. H., Illeperuma, A., Svarovskaia, E., Brainard, D. M., Symonds, W. T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316145 · Cited by 795
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Symonds, W. T., Hindes, R. G., & Berrey, M. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208953 · Cited by 764
ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Ferenci, P., Bernstein, D., Lalezari, J., Cohen, D., Luo, Y., Cooper, C., Tam, E., Marinho, R. T., Tsai, N., Nyberg, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402338 · Cited by 693
Roth, D., Nelson, D. R., Bruchfeld, A., Liapakis, A., Silva, M., Monsour, H., Martin, P., Pol, S., Londoño, M.-C., Hassanein, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00349-9 · Cited by 671
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Lok, A. S.-F., Gardiner, D., Lawitz, E., Martorell, C. T., Everson, G. T., Ghalib, R. H., Reindollar, R., Rustgi, V. K., McPhee, F., Wind‐Rotolo, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1104430 · Cited by 653
McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331702 · Cited by 616
Sarrazin, C., Kieffer, T. L., Bartels, D., Hanzelka, B., Müh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H., Lin, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.037 · Cited by 616
Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus
Bressanelli, S., Tomei, L., Roussel, A., Incitti, I., Vitale, R. L., Mathieu, M., De Francesco, R., & Rey, F. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13034 · Cited by 586
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
Scheel, T. K. H., & Rice, C. M. (2013) · Nature Medicine · doi:10.1038/nm.3248 · Cited by 554
Lawitz, E., Poordad, F. F., Pang, P. S., Hyland, R. H., Ding, X., Mo, H., Symonds, W. T., McHutchison, J. G., & Membreno, F. E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62121-2 · Cited by 547
Love, R. A., Parge, H. E., Wickersham, J. A., Hostomsky, Z., Habuka, N., Moomaw, E. W., Adachi, T., & Hostomska, Z. (1996) · Cell · doi:10.1016/s0092-8674(00)81350-1 · Cited by 509
Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase
Tellinghuisen, T. L., Marcotrigiano, J., & Rice, C. M. (2005) · Nature · doi:10.1038/nature03580 · Cited by 486
Hézode, C., Fontaine, H., Dorival, C., Larrey, D. G., Zoulim, F., Canva, V., de Lédinghen, V., Poynard, T., Samuel, D., Bourlière, M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.035 · Cited by 443
Jacobson, I. M., Dore, G. J., Foster, G. R., Fried, M. W., Radu, M., Rafalsky, V. V., Moroz, L., Craxi, A., Peeters, M., Lenz, O., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60494-3 · Cited by 437
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
Bartenschlager, R., Lohmann, V., & Penin, F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3046 · Cited by 402
Yao, N., Reichert, P., Taremi, S. S., Prosise, W. W., & Weber, P. C. (1999) · Structure · doi:10.1016/s0969-2126(00)80025-8 · Cited by 391
Manns, M., Marcellin, P., Poordad, F., de Araujo, E. S. A., Buti, M., Horsmans, Y., Janczewska, E., Villamil, F., Scott, J., Peeters, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60538-9 · Cited by 376
A genome-wide genetic screen for host factors required for hepatitis C virus propagation
Li, Q., Brass, A. L., Ng, A., Hu, Z., Xavier, R. J., Liang, T. J., & Elledge, S. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907439106 · Cited by 352
Manns, M., Pol, S., Jacobson, I. M., Marcellin, P., Gordon, S. C., Peng, C.-Y., Chang, T.-T., Everson, G. T., Heo, J., Gerken, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61059-x · Cited by 342
Structural basis for RNA replication by the hepatitis C virus polymerase
Appleby, T. C., Perry, J. K., Murakami, E., Barauskas, O., Feng, J., Cho, A., Fox, D., Wetmore, D. R., McGrath, M. E., Ray, A. S., et al. (2015) · Science · doi:10.1126/science.1259210 · Cited by 339
Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus
Love, R. A., Brodsky, O., Hickey, M. J., Wells, P. A., & Cronin, C. N. (2009) · Journal of Virology · doi:10.1128/jvi.02352-08 · Cited by 281
Bourlière, M., Bronowicki, J.-P., de Ledinghen, V., Hézode, C., Zoulim, F., Mathurin, P., Tran, A., Larrey, D. G., Ratziu, V., Alric, L., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70050-2 · Cited by 280
Sofia, M. J., Chang, W., Furman, P. A., Mosley, R. T., & Ross, B. S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201384j · Cited by 275
Kwong, A. D., Kauffman, R. S., Hurter, P., & Mueller, P. (2011) · Nature Biotechnology · doi:10.1038/nbt.2020 · Cited by 274
Summa, V., Ludmerer, S. W., McCauley, J. A., Fandozzi, C., Burlein, C., Claudio, G., Coleman, P. J., DiMuzio, J. M., Ferrara, M., Di Filippo, M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-12 · Cited by 259
Zeuzem, S., Berg, T., Gane, E. J., Ferenci, P., Foster, G. R., Fried, M. W., Hézode, C., Hirschfield, G. M., Jacobson, I. M., Nikitin, I. G., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.058 · Cited by 248
Svarovskaia, E. S., Dvory‐Sobol, H., Parkin, N. T., Hebner, C. M., Gontcharova, V., Martin, R., Ouyang, W., Han, B., Xu, S., Ku, K. S., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu697 · Cited by 226
The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
Romano, K. P., Ali, A., Aydin, C., Soumana, D., Özen, A., Deveau, L. M., Silver, C., Cao, H., Newton, A., Petropoulos, C. J., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002832 · Cited by 219
Biswal, B. K., Cherney, M. M., Wang, M., Chan, L., Yannopoulos, C. G., Bilimoria, D., Nicolas, O., Bedard, J., & James, M. N. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413410200 · Cited by 195
Romano, K. P., Ali, A., Royer, W. E., & Schiffer, C. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006370107 · Cited by 189
Ribeiro, R. M., Li, H., Wang, S., Stoddard, M. B., Learn, G. H., Korber, B., Bhattacharya, T., Guedj, J., Parrish, E. H., Hahn, B. H., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002881 · Cited by 179
Di Marco, S., Volpari, C., Tomei, L., Altamura, S., Harper, S., Narjes, F., Koch, U., Rowley, M., De Francesco, R., Migliaccio, G., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505423200 · Cited by 165
Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir"
Dore, G. J., & Feld, J. J. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ197 · Cited by 165
Self-citationPowdrill, M. H., Tchesnokov, E. P., Kozak, R. A., Russell, R. S., Martin, R., Svarovskaia, E. S., Mo, H., Kouyos, R. D., & Götte, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105797108 · Cited by 162
Self-citationBerger, C., Romero‐Brey, I., Radujković, D., Terreux, R., Zayas, M., Paul, D., Harak, C., Hoppe, S., Gao, M., Pénin, F., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.019 · Cited by 158
Kohli, A., Osinusi, A., Sims, Z., Nelson, A., Meissner, E. G., Barrett, L. L., Bon, D., Marti, M. M., Silk, R., Kotb, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61228-9 · Cited by 150
He, S., Lin, B., Chu, V., Hu, Z., Hu, X., Xiao, J., Wang, A. Q., Schweitzer, C. J., Li, Q., Imamura, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010286 · Cited by 150
Hepatitis C virus NS5A: enigmatic but still promiscuous 10 years on!
Ross-Thriepland, D., & Harris, M. (2015) · Journal of General Virology · doi:10.1099/jgv.0.000009 · Cited by 130
Belema, M., & Meanwell, N. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500335h · Cited by 124
The Changing Epidemiology and Natural History of Hepatitis C Virus Infection
Bialek, S. R., & Terrault, N. A. (2006) · Clinics in Liver Disease · doi:10.1016/j.cld.2006.08.003 · Cited by 120
Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA
Ascher, D. B., Wielens, J., Nero, T. L., Doughty, L., Morton, C. J., & Parker, M. W. (2014) · Scientific Reports · doi:10.1038/srep04765 · Cited by 115
Verdegem, D., Badillo, A., Wieruszeski, J., Landrieu, I., Leroy, A., Bartenschlager, R. F. W., Pénin, F., Lippens, G. M., & Hanoulle, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.182436 · Cited by 105
Poordad, F. F., Sievert, W., Mollison, L. C., Bennett, M., Tse, E., Bräu, N., Levin, J. M., Sepe, T. E., Lee, S. S., Angus, P., et al. (2015) · JAMA · doi:10.1001/jama.2015.3860 · Cited by 102
Lambert, S., Langley, D. R., Garnett, J. A., Angell, R. M., Hedgethorne, K., Meanwell, N. A., & Matthews, S. (2014) · Protein Science · doi:10.1002/pro.2456 · Cited by 100
Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use
Dyson, J. K., Hutchinson, J., Harrison, L., Rotimi, O., Tiniakos, D., Foster, G. R., Aldersley, M. A., & McPherson, S. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.041 · Cited by 96
A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C
Jacobson, I. M., Pawlotsky, J., Afdhal, N. H., Dusheiko, G. M., Forns, X., Jensen, D. M., Poordad, F. F., & Schulz, J. (2012) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2012.01590.x · Cited by 91
Krishnan, P., Tripathi, R. L., Schnell, G., Reisch, T., Beyer, J. M., Dekhtyar, T., Irvin, M., Xie, W., Larsen, L. M., Podsadecki, T. J., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30071-4 · Cited by 83
Kwo, P. Y., Gitlin, N., Nahass, R., Bernstein, D. E., Rojter, S. E., Schiff, E., Davis, M. N., Ruane, P. J., Younes, Z. H., Kalmeijer, R., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30168-9 · Cited by 70
Welker, M., Luhne, S., Lange, C. M., Vermehren, J., Farnik, H., Herrmann, E. M., Welzel, T. M., Zeuzem, S., & Sarrazin, C. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.034 · Cited by 69
Lawitz, E., Matusow, G., DeJesus, E., Yoshida, E. M., Felizarta, F., Ghalib, R. H., Godofsky, E. W., Herring, R., Poleynard, G. D., Sheikh, A. M., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30158-6 · Cited by 66
The Domain 2 of the HCV NS5A Protein Is Intrinsically Unstructured
Hanoulle, X., Badillo, A., Verdegem, D., Pénin, F., & Lippens, G. M. (2010) · Protein and Peptide Letters · doi:10.2174/092986610791498920 · Cited by 56
Nettles, J. H., Stanton, R. A., Broyde, J., Amblard, F., Zhang, H., Zhou, L., Shi, J., McBrayer, T. R., Whitaker, T., Coats, S. J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501291c · Cited by 54
Targets for Antiviral Therapy of Hepatitis C
Rupp, D., & Bartenschlager, R. F. W. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1371006 · Cited by 53
Barakat, K., Anwar‐Mohamed, A., Tuszyński, J. A., Robins, M. J., Tyrrell, D. L., & Houghton, M. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400631n · Cited by 51
Host-targeting agents in the treatment of hepatitis C: A beginning and an end?
Baugh, J., Garcia-Rivera, J. A., & Gallay, P. A. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.020 · Cited by 51
Liang, Y., Ishida, H., Lenz, O., Lin, T., Nyanguile, O., Simmen, K., Pyles, R. B., Bourne, N., Yi, M., Li, K., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.023 · Cited by 49
Poordad, F. F., Lawitz, E., Gutierrez, J. A., Evans, B., Howe, A., Feng, H.-P., Li, J. J., Hwang, P. M. T., Robertson, M. N., Wahl, J., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30013-1 · Cited by 47
Zeuzem, S., Ghalib, R., Reddy, K. R., Pockros, P. J., Ben‐Ari, Z., Zhao, Y., Brown, D. C., DiNubile, M. J., Robertson, M. N., Wahl, J., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30056-8 · Cited by 15
Cited by
Current therapy for chronic hepatitis C: The role of direct-acting antivirals
Li, G., & De Clercq, E. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.02.014 · Cited by 174
“dasabuvir) bind to the allosteric binding pockets outside the NS5B catalytic site based on the non-competitive mechanisms of action that inhibit the RNA synthesis (Gotte and Feld, 2016).”
Optimization of AAV vectors to target persistent viral reservoirs
Colón-Thillet, R., Jerome, K. R., & Stone, D. (2021) · Virology Journal · doi:10.1186/s12985-021-01555-7 · Cited by 50
Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis
Cui, A., Li, B., Wallace, M. S., Gonye, A. L. K., Oetheimer, C., Patel, H., Tonnerre, P., Holmes, J. A., Lieb, D., Yao, B. S., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.040 · Cited by 46
Metadata
- Authors
- Götte, M., & Feld, J. J.
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2016-05-05
- Volume
- 13
- Issue
- 6
- Pages
- 338-351
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W2346961068
- Cited by
- 179
- References
- 80
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.